

July 6, 2009

Commissioner for Patents

(202) 772-8822 INTERNET ADDRESS: SCARROLL@SKGF.COM

WRITER'S DIRECT NUMBER: Art Unit 1647

PO Box 1450 Alexandria, VA 22313-1450

> Re: U.S. Utility Patent Application

> > Application No. 10/587,714; § 371(c) Date: June 4, 2007

Treatment of Conditions Involving Dopaminergic Neuronal Degeneration Using Nogo Receptor Antagonists

Inventors: RELTON et al.

Our Ref: 2681.0450001/SAC/JBF

Sir:

Transmitted herewith for appropriate action are the following documents:

- 1. Reply to Requirement For Election of Species; and
- Petition for Extension of Time Under 37 CFR 1.136(a).

The above-listed documents are filed electronically through EFS-Web.

In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency. or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Shannon A. Carroll, Ph.D. Attorney for Applicants Registration No. 58,240

SAC/ JBF:amr Enclosures 987800 1.DOC